Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can your genes predict blood thinner success? new study targets caribbean hispanics

NCT ID NCT03419325

Knowledge-focused Sponsor: University of Puerto Rico Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at 150 Caribbean Hispanic adults with heart disease or stroke risk who take the blood thinner clopidogrel. Researchers wanted to see if certain gene variants affect how well the drug works. The goal is to understand why some people get less benefit and to pave the way for more personalized treatment in this diverse population.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Early phase 1

The earliest testing in people: a first look at safety, in a very small group.

Participants

150 people

The number who actually took part.

Started

Sep 2020

Finished

Dec 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

21 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Caribbean Hispanics (Puerto Ricans, Dominicans or Cubans) residing in Puerto Rico, whose parents are also of Hispanic origin * Both genders (Males/Females) * Age ≥21 * Receiving Clopidogrel for therapeutic indications. * No clinically active hepatic abnormality * The ability to understand the requirements of the study * The ability to comply with study procedures and protocol * A female patient is eligible to enter the study if she is of child-bearing potential and not pregnant or nursing, or not of child-bearing potential Exclusion Criteria: * Non-Hispanic patients (race/ethnicity is self-reported by the patients) * Currently enrolled in another active research protocols at the participating institutions * BUN \>30 * Creatinine \>2.0 mg/dL * Platelet count \<100,000/mm3 * Nasogastric or enteral feedings * Acute illness (e.g., sepsis, infection, anemia) * HIV/AIDS, Hepatitis B patients * Alcoholism and drug abuse * Patients with any cognitive and mental health impairment * Sickle cell patients * Active malignancy * Patients taking another antiplatelet

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute coronary syndrome are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute coronary syndrome cardiovascular disorder coronary artery disorder myocardial infarction peripheral arterial disease stroke disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute coronary syndrome Cardiovascular disease (CVD) Coronary artery disease Myocardial infarction Peripheral arterial disease Stroke

Contacts and locations

Locations

  • Cardiovascular Hospital of Puerto Rico and the Caribbean

    San Juan, 00926, Puerto Rico

  • University Hospital at Carolina

    Carolina, 00984, Puerto Rico

More trials for these conditions

Other studies related to the condition(s) this trial covers.